investorscraft@gmail.com

Stock Analysis & ValuationCitius Oncology, Inc. (CTOR)

Previous Close
$0.94
Sector Valuation Confidence Level
High
Valuation methodValue, $Upside, %
Artificial intelligence (AI)n/an/a
Intrinsic value (DCF)n/a
Graham-Dodd Methodn/a
Graham Formulan/a

Company Information

420 Lexington Avenue
New York City, NY 10170
United States
Phone: 347-627-0058
Industry: Drug Manufacturers - General
Sector: Healthcare
CEO: Leonard L. Mazur

Citius Oncology, Inc. focuses on the development of novel targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma. The company is headquartered in New York, New York. Citius Oncology, Inc. operates as a subsidiary of Citius Pharmaceuticals, Inc.

HomeMenuAccount